These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 144049)

  • 21. Deanol in the management of involuntary movement disorders: a review.
    Casey DE
    Dis Nerv Syst; 1977 Dec; 38(12 Pt 2):7-15. PubMed ID: 145359
    [No Abstract]   [Full Text] [Related]  

  • 22. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
    Degkwitz R
    Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurotransmitter interactions related to central dopamine neurons.
    Lloyd KG
    Essays Neurochem Neuropharmacol; 1978; 3():129-207. PubMed ID: 30628
    [No Abstract]   [Full Text] [Related]  

  • 24. The pharmacology of choreatic movement disorders.
    Klawans HL; Weiner WJ
    Prog Neurobiol; 1976; 6(1):49-80. PubMed ID: 132681
    [No Abstract]   [Full Text] [Related]  

  • 25. Parkinson's disease, Huntington's disease and tardive dyskinesia. Neurochemical pathology and treatment.
    Tolosa ES
    Minn Med; 1979 Feb; 62(2):101-6. PubMed ID: 155195
    [No Abstract]   [Full Text] [Related]  

  • 26. Serotonergic-dopaminergic interactions and extrapyramidal function.
    Chase TN
    Adv Biochem Psychopharmacol; 1974; 11(0):377-85. PubMed ID: 4367649
    [No Abstract]   [Full Text] [Related]  

  • 27. Current concepts in the management of movement disorders.
    Olanow CW
    Clin Neurosurg; 1981; 28():137-70. PubMed ID: 6119175
    [No Abstract]   [Full Text] [Related]  

  • 28. Biochemical interactions in the basal ganglia.
    McGeer PL; McGeer EG; Hattori T
    Prog Brain Res; 1979; 51():285-301. PubMed ID: 95234
    [No Abstract]   [Full Text] [Related]  

  • 29. Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review.
    Jamwal S; Kumar P
    Curr Neuropharmacol; 2019; 17(2):165-175. PubMed ID: 29512464
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of d-amphetamine on choreiform movement disorders.
    Klawans HL; Weiner WJ
    Neurology; 1974 Apr; 24(4):312-8. PubMed ID: 4274157
    [No Abstract]   [Full Text] [Related]  

  • 31. Opposite effect of harmaline on seotonin and on dopamine and its metabolites, homovanillic acid and norepinephrine, in the brain of the cat.
    Poirier LJ; Singh P; Boucher R
    Can J Physiol Pharmacol; 1968 Jul; 46(4):585-9. PubMed ID: 5302163
    [No Abstract]   [Full Text] [Related]  

  • 32. [Experimental findings and new aspects in extrapyramidal diseases].
    Birkmayer W
    Wien Z Nervenheilkd Grenzgeb; 1966; 23(1):128-39. PubMed ID: 4226878
    [No Abstract]   [Full Text] [Related]  

  • 33. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.
    Bartholini G
    Adv Biochem Psychopharmacol; 1977; 16():607-11. PubMed ID: 18902
    [No Abstract]   [Full Text] [Related]  

  • 34. The neuropharmacology of abnormal involuntary movement disorders (the dyskinesias).
    Marsden CD
    Mod Trends Neurol; 1975; 6():141-66. PubMed ID: 127927
    [No Abstract]   [Full Text] [Related]  

  • 35. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurochemical basis for pathological motor activity].
    Hole K
    Tidsskr Nor Laegeforen; 1974 Jan; 94(1):11-7. PubMed ID: 4362478
    [No Abstract]   [Full Text] [Related]  

  • 37. The biochemistry of the basal ganglia and Parkinson's disease.
    Curzon G
    Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
    Jiménez-Jiménez FJ; Molina JA; Ortí-Pareja M
    Rev Neurol; 1999 May 1-15; 28(9):889-98. PubMed ID: 10390756
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of dopamine in the nervous system.
    Barbeau A
    Monogr Hum Genet; 1972; 6():114-36. PubMed ID: 4577118
    [No Abstract]   [Full Text] [Related]  

  • 40. [Dopamine and the parkinsonism-chorea antagonism].
    Bulandra R; Serbanesco A
    Rev Neurol (Paris); 1972 Aug; 127(2):315. PubMed ID: 4147105
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.